Vaccinex was founded in 1997 to commercialize antibody platform technology developed at the University of Rochester Medical Center by co-founders Maurice Zauderer, PhD and Deepak Sahasrabudhe, MD.
Vaccinex, Inc. awarded three Qualifying Therapeutic Discovery Project (QTDP) grants under the Patient Protection and Affordable Care Act of 2010 (PPACA)
Vaccinex, Inc. announced today that it has been awarded three grants by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of the company’s three lead therapeutic monoclonal antibodies, VX15, VX5 and VX35. The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. read more